Sign In
Last checked at 
4 Apr 2017 17:47
Creo Medical Group plc
Director/PDMR Dealing
The Company has been informed that directors Craig Gulliford (Chief Executive Officer) and Chris Hancock (Chief Technology Officer) have today each transferred ordinary shares of 0.1p each ("Ordinary Shares") in the Company from their personal holdings to their self-invested personal pensions ("SIPP"), as follows.
Director | Number of Ordinary Shares sold from personal account | Price per Ordinary Share sold | Number of Ordinary Shares purchased into SIPP | Price paid per Ordinary Share by SIPP |
Craig Gulliford | 92,750 | 82.5p | 92,704 | 82.5p |
Chris Hancock | 106,084 | 82.5p | 106,038 | 82.5p |
Following these transactions, Mr Gulliford and Mr Hancock's total interest in the Company are 1,089,886 Ordinary Shares and 4,880,150 Ordinary Shares respectively.
Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||||
a)
| Name
| Craig Gulliford
| ||||||
2
| Reason for the notification
| |||||||
a)
| Position/status
| Chief Executive Officer | ||||||
b)
| Initial notification /Amendment
| Initial | ||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||||
a)
| Name
| Creo Medical Group plc | ||||||
b)
| LEI
| N/A | ||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||||
a)
| Description of the financial instrument, type of instrument
Identification code
|
Ordinary shares of £0.001 each
GB00BZ1BLL44 | ||||||
b)
| Nature of the transaction
| Transfer of ordinary shares to self-invested personal pension (SIPP) via sale and purchase | ||||||
c)
| Price(s) and volume(s)
|
| ||||||
d)
| Aggregated information
- Aggregated volume
- Price
|
Weighted average price of 82.5p per share
| ||||||
e)
| Date of the transaction
| 4 April 2017 | ||||||
f)
| Place of the transaction
| London Stock Exchange | ||||||
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||||
a)
| Name
| Chris Hancock
| ||||||
2
| Reason for the notification
| |||||||
a)
| Position/status
| Chief Technology Officer | ||||||
b)
| Initial notification /Amendment
| Initial | ||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||||
a)
| Name
| Creo Medical Group plc | ||||||
b)
| LEI
| N/A | ||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||||
a)
| Description of the financial instrument, type of instrument
Identification code
|
Ordinary shares of £0.001 each
GB00BZ1BLL44 | ||||||
b)
| Nature of the transaction
| Transfer of ordinary shares to self-invested personal pension (SIPP) via sale and purchase | ||||||
c)
| Price(s) and volume(s)
|
| ||||||
d)
| Aggregated information
- Aggregated volume
- Price
|
Weighted average price of 82.5p per share
| ||||||
e)
| Date of the transaction
| 4 April 2017 | ||||||
f)
| Place of the transaction
| London Stock Exchange | ||||||
Contacts
Creo Medical: | Cenkos: | FTI Consulting: |
Roseanne Varner +44 (0)129 160 6005 roseanne.varner@creomedical.com | Ivonne Cantu / Camilla Hume (NOMAD) Michael Johnson / Russell Kerr (Sales) +44 (0)207 397 8900 | Brett Pollard / Mo Noonan +44 (0)203 727 1000 creo@fticonsulting.com |
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring the CROMA surgical system to market through a suite of medical instruments which the Company has designed, initially for GI therapeutic endoscopy, an area with high unmet needs. The CROMA system will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website, www.creomedical.com.
Follow the stocks
